Drug Delivery & Environmental Sustainability159

Issue No #159 April/May 2024 May 9th, 2024

Issue 159 - AprMay 2024

Inside the magazine

INTERVIEW: THE BENEFITS OF BEING AN EARLY ADOPTER OF SUSTAINABILITY PRINCIPLES

INTERVIEW: THE BENEFITS OF BEING AN EARLY ADOPTER OF SUSTAINABILITY PRINCIPLES

Reto Jost and Gabriel Kalbermatter talk exclusively with ONdrugDelivery's Guy Furness, discussing the progress Ypsomed has made in advancing its sustainability agenda, particularly the implementation of its ecodesign guideline, the benefits of being an early adopter of sustainability principles, how YpsoMate 5.5 mL has been designed from the ground up with sustainability in mind and where sustainability considerations currently fit into the wider pharma industry.

DESIGN FOR SUSTAINABILITY – THE CONSIDERATIONS BROUGHT TO LIFE

DESIGN FOR SUSTAINABILITY – THE CONSIDERATIONS BROUGHT TO LIFE

Oli Gould explores the use of lifecycle assessment in product design for sustainability to impact the environment positively.

INTERVIEW with Dora Rio, Head of Sustainability, SHL Medical

INTERVIEW with Dora Rio, Head of Sustainability, SHL Medical

Dora Rio discusses various aspects of SHL's approach to sustainability, including how it interacts with other players up and down the value chain, whether reusable or single-use devices are more sustainable and how SHL addresses sustainability concerns beyond CO₂.

SUSTAINABLE BY DESIGN: DEVELOPING PATIENT- AND PLANET-CENTRIC MEDICAL DEVICES

SUSTAINABLE BY DESIGN: DEVELOPING PATIENT- AND PLANET-CENTRIC MEDICAL DEVICES

Su Osorio, Stephanie Mou and Charlie Dean, explore the delicate balance between patient and planet centricity and propose a user- and planet-centric approach for the development of sustainable medical devices.

TOWARDS A COMPREHENSIVE SUSTAINABILITY STRATEGY

Dr Marie-Christine Klein

TOWARDS A COMPREHENSIVE SUSTAINABILITY STRATEGY

Marie-Christine Klein and Christian Weyler, look at the evolution of the company’s sustainability strategy within its regulatory and economic framework – and what decarbonisation means for the pharmaceutical industry.

SUSTAINABILITY PROGRAMMES: EVERY STEP COUNTS

SUSTAINABILITY PROGRAMMES: EVERY STEP COUNTS

Henryk Badack shares insights into the current state of sustainability in the pharma and biotech industry, how sustainability commitments vary between organisations and what companies can do to develop sustainability strategies that will last.

PCI’S ESG JOURNEY – ESTABLISHING PROCESSES AND DRIVING RESULTS

Gigi Bat-Erdene

PCI Pharma Services

PCI’S ESG JOURNEY – ESTABLISHING PROCESSES AND DRIVING RESULTS

Gigi Bat-Edene discusses the steps that PCI has taken towards realising its environmental, social and governance targets and achieving reductions in its greenhouse gas emissions in the journey towards net zero.

NAVIGATING THE TRANSITION TO SUSTAINABLE MEDICAL PROPELLANTS

Dr Timothy Noakes

NAVIGATING THE TRANSITION TO SUSTAINABLE MEDICAL PROPELLANTS

Timothy Noakes, Sheryl Johnson and Richard Greenhough, discuss the status of the current move from high-global-warming-potential propellants for pressurised metered dose inhalers to more sustainable alternatives.

OPTIMISING LOW-GWP pMDI SPRAYS FOR ENHANCED PERFORMANCE AND SUSTAINABILITY

Dr Benjamin Myatt

OPTIMISING LOW-GWP pMDI SPRAYS FOR ENHANCED PERFORMANCE AND SUSTAINABILITY

Benjamin Myatt and Daniel Duke explore the low-global-warming-potential propellants available and their implications for the performance of pressurised metered dose inhalers.

CHANGE IS IN THE AIR: THE FUTURE CLIMATE OF INHALED MEDICATION

Pauline Janssen

CHANGE IS IN THE AIR: THE FUTURE CLIMATE OF INHALED MEDICATION

Pauline Janssen, discusses the various available devices for pulmonary delivery of medications, with a deeper dive into the challenges presented by replacing pMDI propellants with high global warming potential with new alternatives, or whether the optimal solution could be phasing out pMDIs in favour of DPIs.

PHARMACEUTICAL INDUSTRY SUSTAINABILITY TARGETS, ONE YEAR ON

Catriona Eldridge

PHARMACEUTICAL INDUSTRY SUSTAINABILITY TARGETS, ONE YEAR ON

Catriona Eldridge, analyses whether the pharmaceutical industry is meeting its targets and doing enough in the fight against climate change.

REUSABLE VERSUS SINGLE-USE DEVICES: TRADE-OFFS IN IMPROVING SUSTAINABILITY

Alastair Willoughby

REUSABLE VERSUS SINGLE-USE DEVICES: TRADE-OFFS IN IMPROVING SUSTAINABILITY

Alastair Willoughby and Prem-Sagar Tank, explore various device trade-offs for both sustainability and cost in reusable injection devices, and consider how this compares with single-use devices.

LEVERAGING AI & BIG DATA FOR ECO-DESIGN COLLABORATION IN PHARMA

LEVERAGING AI & BIG DATA FOR ECO-DESIGN COLLABORATION IN PHARMA

Alissa Monk, Kami Krista, Cédric Montagnetegy and Carole Schanté, explore the potential of artificial intelligence and big data in eco-design with the aim of transforming the pharmaceutical industry towards greater sustainability.

SCALING GLP-1 DRUGS WITHOUT A MOUNTAIN OF WASTE

SCALING GLP-1 DRUGS WITHOUT A MOUNTAIN OF WASTE

Matt Parker, Simon Lyons and Alex Lyness, look at how the continued success of glucagon-like peptide-1 drugs is bringing into focus the need for environmentally sustainable self-injection systems. They discuss whether reloadable autoinjectors could be the way to boost sustainability, lower cost per dose, and match the scale and rate of adoption of these new therapies.

Top